{"id":558772,"date":"2026-07-15T12:30:00","date_gmt":"2026-07-15T10:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=558772"},"modified":"2026-07-15T13:19:10","modified_gmt":"2026-07-15T11:19:10","slug":"inhibidores-de-sglt-2-y-agonistas-selectivos-del-glp-1-mejora-significativa-de-los-criterios-de-valoracion-renales","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/es\/inhibidores-de-sglt-2-y-agonistas-selectivos-del-glp-1-mejora-significativa-de-los-criterios-de-valoracion-renales\/","title":{"rendered":"Inhibidores de SGLT-2 y agonistas selectivos del GLP-1: mejora significativa de los criterios de valoraci\u00f3n renales"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Aproximadamente entre el 30 % y el 40 % de los pacientes con diabetes tipo 2 desarrollan, a lo largo de la enfermedad, una enfermedad renal cr\u00f3nica (ERC). En estudios \u00abreferentes\u00bb como CREDENCE, DAPA-CKD, EMPA-KIDNEY y algunos otros,<em> los inhibidores de SGLT-2 (transportador de sodio-glucosa 2)<\/em>obtuvieron beneficios demostrables en los criterios de valoraci\u00f3n renales; adem\u00e1s, el estudio FLOW ha demostrado ahora que el<em> GLP-1 (p\u00e9ptido similar al glucag\u00f3n tipo 1)<\/em>se han demostrado efectos nefroprotectores significativos en personas con diabetes tipo 2.   <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Finhibidores-de-sglt-2-y-agonistas-selectivos-del-glp-1-mejora-significativa-de-los-criterios-de-valoracion-renales%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Aproximadamente entre el 30 % y el 40 % de los pacientes con diabetes tipo 2 desarrollan, a lo largo de la enfermedad, una enfermedad renal cr\u00f3nica (ERC). En estudios&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Finhibidores-de-sglt-2-y-agonistas-selectivos-del-glp-1-mejora-significativa-de-los-criterios-de-valoracion-renales%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":558774,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Enfermedad renal cr\u00f3nica en personas con diabetes tipo 2: tratamiento optimizado basado en la evidencia","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11552,11352,11475,11478,11288,11377],"tags":[24275,94796,66558,23317,12033,94802,44103,13028,13023,94800,20820,65639,94797,94799,18648],"powerkit_post_featured":[],"class_list":["post-558772","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-es","category-endocrinologia-y-diabetologia","category-estudios","category-formacion-continua","category-medicina-interna-general","category-nefrologia","tag-canagliflozina","tag-credence","tag-dapa-ckd-es","tag-dapagliflozina","tag-diabetes-tipo-2-es-2","tag-efectos-nefroprotectores","tag-empagliflozina","tag-enfermedad-renal-cronica","tag-erc","tag-estudio-flow","tag-forxiga-es","tag-glp-1-ra-es-2","tag-jardiance","tag-ozempic","tag-sglt-2-i-es","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-28 17:03:36","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"es_ES","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/558772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/comments?post=558772"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/558772\/revisions"}],"predecessor-version":[{"id":561392,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/558772\/revisions\/561392"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media\/558774"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media?parent=558772"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/category?post=558772"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/tags?post=558772"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/powerkit_post_featured?post=558772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}